Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Sales and Divestitures (2017 - 2025)

UroGen Pharma's Gains from Sales and Divestitures history spans 9 years, with the latest figure at $557380.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 44.75% year-over-year to $557380.0; the TTM value through Dec 2025 reached $557380.0, up 44.75%, while the annual FY2025 figure was $557380.0, 44.75% up from the prior year.
  • Gains from Sales and Divestitures reached $557380.0 in Q4 2025 per URGN's latest filing, up from $385065.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $557380.0 in Q4 2025 to a low of $283147.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $378702.2, with a median of $374293.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 229.42% in 2021, then decreased 21.55% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $283147.0 in 2021, then soared by 32.19% to $374293.0 in 2022, then fell by 21.55% to $293626.0 in 2023, then skyrocketed by 31.14% to $385065.0 in 2024, then skyrocketed by 44.75% to $557380.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Gains from Sales and Divestitures are $557380.0 (Q4 2025), $385065.0 (Q4 2024), and $293626.0 (Q4 2023).